221 related articles for article (PubMed ID: 29259533)
21. Exploring Solutions to Foster ATMP Development and Access to Patients in Europe.
Salvatore V
Eur J Health Law; 2020 May; 27(3):259-273. PubMed ID: 33652396
[TBL] [Abstract][Full Text] [Related]
22. A comprehensive resource on EU regulatory information for investigators in gene therapy clinical research and advanced therapy medicinal products.
Cohen-Haguenauer O
Hum Gene Ther; 2013 Jan; 24(1):12-8. PubMed ID: 23339285
[No Abstract] [Full Text] [Related]
23. Regulatory approval pathways for anticancer drugs in Japan, the EU and the US.
Nagai S; Ozawa K
Int J Hematol; 2016 Jul; 104(1):73-84. PubMed ID: 27084259
[TBL] [Abstract][Full Text] [Related]
24. Development and regulation of biosimilars: current status and future challenges.
Tsiftsoglou AS; Ruiz S; Schneider CK
BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
[TBL] [Abstract][Full Text] [Related]
25. Regional Differences During the ICH Regulatory Consultation Process Between the EU, US, and Japan.
Torqui A; Macau AM
Ther Innov Regul Sci; 2018 Jul; 52(4):438-441. PubMed ID: 29714552
[TBL] [Abstract][Full Text] [Related]
26. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
Kroes BH
J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
[TBL] [Abstract][Full Text] [Related]
27. Decision and timing of safety-related labeling changes for new drugs in Japan: Comparison with the United States and the European Union.
Fukuda K; Narukawa M
Pharmacoepidemiol Drug Saf; 2023 Dec; 32(12):1331-1340. PubMed ID: 37395168
[TBL] [Abstract][Full Text] [Related]
28. Gene therapy regulation: could in-body editing fall through the net?
Mourby M; Morrison M
Eur J Hum Genet; 2020 Jul; 28(7):979-981. PubMed ID: 32214228
[TBL] [Abstract][Full Text] [Related]
29. Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe.
Ten Ham RMT; Hoekman J; Hövels AM; Broekmans AW; Leufkens HGM; Klungel OH
Mol Ther Methods Clin Dev; 2018 Dec; 11():121-130. PubMed ID: 30456217
[TBL] [Abstract][Full Text] [Related]
30. Regulatory requirements for clinical trial and marketing authorisation application for gene therapy medicinal products.
Schüle S; Renner M; Longhurst S; Narayanan G
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):30-7. PubMed ID: 20012927
[TBL] [Abstract][Full Text] [Related]
31. New Japanese Regulatory Frameworks for Clinical Research and Marketing Authorization of Gene Therapy and Cellular Therapy Products.
Nagai S; Ozawa K
Curr Gene Ther; 2017; 17(1):17-28. PubMed ID: 28382858
[TBL] [Abstract][Full Text] [Related]
32. Overcoming Challenges Facing Advanced Therapies in the EU Market.
Abou-El-Enein M; Elsanhoury A; Reinke P
Cell Stem Cell; 2016 Sep; 19(3):293-7. PubMed ID: 27588746
[TBL] [Abstract][Full Text] [Related]
33. Raising Gene Therapy for Unmet Medical Needs in Japan.
Ishii T
JMA J; 2019 Mar; 2(1):73-79. PubMed ID: 33681517
[TBL] [Abstract][Full Text] [Related]
34. [Report from the Committee for Advanced Therapies (CAT). Pitfalls on the way from concept to medical treatment with advanced therapy medicinal products].
Reiss M; Büttel IC; Schneider CK
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):822-30. PubMed ID: 21698535
[TBL] [Abstract][Full Text] [Related]
35. [The certification of advanced therapy medicinal products. A quality label for product development in small and medium-sized enterprises].
Berger A; Schüle S; Flory E
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):816-21. PubMed ID: 21698534
[TBL] [Abstract][Full Text] [Related]
36. [European Marketing Authorisation: a long process. Experiences of small biotech companies with the ATMP regulation].
Buljovčić Z
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):831-8. PubMed ID: 21698536
[TBL] [Abstract][Full Text] [Related]
37. Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development.
Ancans J
Front Immunol; 2012; 3():253. PubMed ID: 22912639
[TBL] [Abstract][Full Text] [Related]
38. Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
Tsuji K; Tsutani K
J Clin Pharm Ther; 2010 Jun; 35(3):289-301. PubMed ID: 20848767
[TBL] [Abstract][Full Text] [Related]
39. The science and practice of current environmental risk assessment for gene therapy: a review.
Liu F
Cytotherapy; 2024 Jul; 26(7):686-699. PubMed ID: 38713109
[TBL] [Abstract][Full Text] [Related]
40. The Landscape of Cellular and Gene Therapy Products: Authorization, Discontinuations, and Cost.
Shukla V; Seoane-Vazquez E; Fawaz S; Brown L; Rodriguez-Monguio R
Hum Gene Ther Clin Dev; 2019 Sep; 30(3):102-113. PubMed ID: 30968714
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
